Vtama (tapinarof 1% cream) — Medica

atopic dermatitis

Preferred products

medium-, medium-high, high-, and super-high potency topical corticosteroids including betamethasone dipropionate, augmented; clobetasol propionate; fluocinonide; halobetasol propionate; and other agents per Table 1

A) Plaque psoriasis: Patient meets BOTH of the following (i and ii):
i. age ≥ 18 years; AND
ii. ONE of the following (a or b):
a) Patient has tried one Step 1 Product (medium-, medium-high, high-, or super-high potency prescription topical corticosteroid); OR
b) Patient is treating plaque psoriasis and meets ONE of the following (1, 2, or 3):
1. Patient has tried one topical vitamin D analog (e.g., calcipotriene, calcitriol, Sorilux); OR
2. Patient has tried one combination product containing a topical vitamin D analog and topical corticosteroid (e.g., Taclonex, Enstilar, Wynzora); OR
3. Patient is treating plaque psoriasis affecting face, eyes/eyelids, skin folds, and/or genitalia.
B) Atopic dermatitis: Patient meets ALL of the following (i, ii, and iii):
i. age > 2 years; AND
ii. diagnosis of atopic dermatitis; AND
iii. ONE of the following (a or b):
a) Patient has tried one prescription topical corticosteroid; OR
b) Patient is treating atopic dermatitis affecting face, eyes/eyelids, axilla, or genitalia.

1 year